-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Even after three years, Andrew Parker and his oncologist, Michael Bishop, m.D., at the University of Chicago Medical Center, are in awe of the amazing turn of CAR-T cell immunotherapy2016, Parker, 59, went to a primary care doctor with swelling in his legHe was shocked to learn that he had invasive acute lymphoblastic leukemia (ALL)The Michigan resident began a series of chemotherapy treatments, but to no availhis health deteriorated rapidlyhis medical team suggested that he contact Bishop, who was leading a clinical trial called CAR-T Cell Immunotherapy, an emergingcancerimmunotherapy"They told me that DrBishop had some new discoveries," Parker said, "i decided to try because I had no choice." "
CAR-T cell immunotherapy to identify tumor cells by reconstructing the patient's own T cells and destroying cancer cells with minimal damage to healthy cellsParker was eligible to participate in the trial, but just days before the trial began, Bishop brought him some disappointing news"
", "We can't experiment," Bishop told himThe U.SFood and Drug Administration (FDA) has suspended CAR-T treatmentParker was disappointedHe returned to his home state of Michigan and believed he was alive soonat the same time, Bishop appealed to the FDABecause Parker's condition is so serious, Bishop asked the FDA to consider using CAR-T cell therapyThe FDA immediately gave Bishop the green light, a week later, Dr Bishop called and said, 'Come back! We can startParker saidParker completed the treatment of CAR-T cell immunotherapyAs expected, for the first few days he was weak and needed intensive careBut by the third day, he was feeling much betterweeks later, a bone marrow biopsy showed no cancer cellsParker's own T-cells kill cancerSince treatment in 2016, the FDA has approved CAR-T cell immunotherapy for the treatment of certain types of leukemia and lymphomaThe University of Chicago Medical Center currently has 15 clinical trials of CAR-T cell immunotherapy for different cancers, including multiple myelomaless than three months later, Parker was back to healthHe returned to a mold shop and returned to his position as manager of the company Now, the 61-year-old is back in his normal life, working, travelling and enjoying life with his fiancee Mary He called Mary a pillar during his battle with cancer " it was like a miracle Parker said Now, Parker needs to regularly intake immunoglobulin to protect himself from infection and disease Weakened immune systemist is a side effect of CAR-T cell immunotherapy every six months, he goes back and forth for seven hours and sees Dr Bishop for 15 minutes as part of his commitment to clinical trials "I went to see Dr Bishop, did some blood tests, and then went home," he said, "every mile was worth it."
Source: University of Chicago Medical Center Review: njwbhuang on 2020-4-11 Review: is another cart cell therapy (from: MedSci Medical APP )